UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
MYLAN PHARMACEUTICALS INC.
Petitioner
v.
JANSSEN ONCOLOGY, INC.
Patent Owner
Case No. IPR2016-01332

DECLARATION OF SHANNON M. BLOODWORTH
IN SUPPORT OF MOTION FOR *PRO HAC VICE* ADMISSION OF
SHANNON M. BLOODWORTH



### I, Shannon M. Bloodworth, declare as follows:

- 1. I am a partner in the patent litigation group at Perkins Coie LLP.
- 2. I am a member in good standing of the Bar of the States of Maryland and Wisconsin, the Commonwealth of Virginia and the District of Columbia. I am also admitted to practice before the United States Courts of Appeals for the Fourth Circuit, D.C. Circuit, and the Federal Circuit. I am admitted to practice before the United States District Courts for D.C. and Maryland, and the Supreme Courts of Virginia and Wisconsin.
- 3. My Bar membership numbers are VA 46671, DC 474925 and WI 1088470.
- 4. I have been practicing law for more than 15 years, during which time I have focused on litigating patent cases, specifically pharmaceutical patent cases.
- 5. More generally, I have represented the Petitioner and/or its various related entities in litigating significant pharmaceutical patent cases, such as the following infringement cases:
  - BTG Int'l Ltd. v. Actavis Labs. FL, Inc., Civil Action No. 2:15-cv-05909 (U.S. District Court for the District of New Jersey);
  - Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc., Civil Action No. 1:14-cv-01278 (U.S. District Court for the District of Delaware);



- Teva Pharmaceuticals USA Inc. v. Sandoz Inc., Civil Action No.
   17-1575 (U.S. Court of Appeals for the Federal Circuit);
- Yeda Research and Development Co. v. Mylan Pharmaceuticals Inc.,
   Civil Action Nos. 17-1594, 17-1595, 17-1596 (U.S. Court of Appeals for the Federal Circuit);
- The Medicines Co. v. Mylan Inc., Civil Action No. 1:11-cv-01285 (U.S. District Court for the Northern District of Illinois);
- The Medicines Co. v. Mylan Inc., Civil Action Nos. 15-1113, 15-1151, 15-1181 (U.S. Court of Appeals for the Federal Circuit);
- AstraZeneca AB v. Mylan Laboratories Ltd., Civil Action No.
   3:12-cv-01378 (U.S. District Court for the District of New Jersey);
- AstraZeneca AB v. Mylan Laboratories Ltd., Civil Action No.
   15-1889 (U.S. Court of Appeals for the Federal Circuit);
- Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc., Civil
  Action No. 1:09-cv-08824 (U.S. District Court for the Southern
  District of New York);
- Teva Pharmaceuticals USA Inc. v. Sandoz Inc., Civil Action Nos. 12-1567, 12-1568, 12-1569, 12-1570 (U.S. Court of Appeals for the Federal Circuit);



- Teva Pharmaceuticals USA Inc. v. Sandoz Inc., Civil Action No.
   13-854 (Supreme Court of the United States);
- Novo Nordisk Inc. v. Mylan Pharmaceutical Inc., Civil Action No.
   3:09-cv-02445 (United States District Court for the District of New Jersey);
- Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc., Civil Action No. 10-cv-7246 (U.S. District Court for the Southern District of New York);
- Teva Neuroscience, Inc. v. Mylan Inc., Civil Action No.
   2:10-cv-05078 (U.S. District Court for the District of New Jersey);
- Teva Neuroscience, Inc. v. Mylan Inc., Civil Action No. 14-1166
   (U.S. Court of Appeals for the Federal Circuit);
- Apotex, Inc. v. Daiichi Sankyo, Inc., Civil Action No. 1:15-cv-03695
   (U.S. District Court for the Northern District of Illinois);
- Apotex, Inc. v. Daiichi Sankyo, Inc., Civil Action Nos. 16-2073,
   16-2075, 16-2076, 16-2078 (U.S. Court of Appeals for the Federal Circuit);
- AstraZeneca Pharmaceuticals LP v. Agila Specialties Inc.., Civil
  Action No. 1:15-cv-06039 (U.S. District Court for the District of New
  Jersey);



- AstraZeneca AB v. Mylan Pharmaceuticals Inc., No. 3:13-cv-04022
   (U.S. District Court for the District of New Jersey);
- Horizon Pharma, Inc. v. Mylan Pharmaceuticals Inc., Civil Action
   No. 15-cv-03327 (U.S. District Court for the District of New Jersey);
   and
- Horizon Pharma, Inc. v. Mylan Pharmaceuticals Inc., Civil Action
   No. 16-cv-04921 (U.S. District Court for the District of New Jersey).
- 6. I have never been disbarred, sanctioned or cited for contempt by any court or administrative body. I am not currently suspended in any bar or by any court or administrative body.<sup>1</sup>
- 7. I have never had a court deny my application for admission to practice.
- 8. I am familiar with the subject matter of this proceeding. In addition to U.S. Patent No. 8,822,438 ("the '438 patent") and its prosecution history, I am familiar with the technology at issue and Zytiga, the pharmaceutical product for which the '438 patent is listed by Janssen in FDA's publication, *Approved Drug*1 In May 2004, during transition to a new law firm, my DC bar dues were inadvertently not paid. As soon as I discovered the non-payment, I immediately paid all outstanding dues and was reinstated. I have been a member in good



standing ever since.

# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

